AVTX
Avalo Therapeutics, Inc.
$18.42
-0.49 (-2.59%)
At close · Jul 14
Market Cap
$975.09M
Shares
52,565,572
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$59K
-86.6%
FY2025
Net Income
-$78.26M
-122.8%
FY2025
Gross Margin
33.26%
-47.7pp
FY2023
Operating Margin
-123601.69%
-108066.1pp
FY2025
Diluted EPS
-$5.84
+72.1%
FY2025
Operating Cash Flow
-$51.46M
-4.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $59K | $441K | $1.92M | $18.05M | $5.4M | $6.7M | $6.75M | $7.03M | $27.81M | $1.15M | $0 | — | — | |
| — | — | — | $1.28M | $3.43M | $1.49M | $300K | -$566.52K | $3.26M | $635.65K | $0 | $0 | — | — | |
| $1.49M | — | — | $640K | $14.62M | $3.91M | $6.4M | $7.32M | $3.77M | $27.18M | $1.15M | $0 | — | — | |
| — | — | — | 33.26% | 80.98% | 72.38% | 95.52% | 108.39% | 53.61% | 97.71% | 100% | — | — | — | |
| $55.01M | $50.08M | $24.44M | $13.78M | $31.31M | $59.84M | $32.19M | $11.76M | $5.79M | $4.37M | $10.15M | $6.59M | $12.24M | $8.91M | |
| $6.29M | — | — | — | — | $2.83M | $2.34M | $1.48M | $545.22K | $569.83K | $0 | $0 | — | — | |
| $24.21M | $22.9M | $17.24M | $10.3M | $20.71M | $24.66M | $17.42M | $10.12M | $10.51M | $7.94M | $7.08M | $4.42M | $4.88M | $4.02M | |
| — | — | — | $10.3M | $20.71M | — | — | — | — | — | — | — | — | — | |
| — | — | — | $0 | $38K | $1.55M | $1.74M | $1.34M | $1.82M | $403.52K | $0 | — | — | — | |
| — | $344K | $169K | $158K | $166K | $1.66M | $1.84M | $3.88M | $4.55M | $425.48K | $26.86K | $23.51K | — | — | |
| $42.67M | — | — | — | — | — | — | — | $57.64M | $13.92M | $17.23M | $11.01M | — | — | |
| $79.22M | $72.98M | $68.95M | $29.28M | $55.49M | $87.53M | $79.54M | $22.89M | $42.41M | — | — | — | — | — | |
| -$79.16M | -$72.93M | -$68.51M | -$27.35M | -$37.44M | -$82.13M | -$72.84M | -$16.14M | -$35.38M | $13.89M | -$16.08M | -$11.01M | -$17.12M | -$12.93M | |
| — | -123601.69% | -15535.6% | -1421.57% | -207.41% | -1521.56% | -1087.37% | -239.06% | -503.37% | 49.94% | -1394.64% | — | — | — | |
| — | -$72.58M | -$68.34M | -$27.19M | -$37.27M | -$80.48M | -$71M | -$12.25M | -$30.82M | $14.32M | -$16.05M | -$10.99M | — | — | |
| -$5.41M | -$5.17M | $33.5M | -$4.18M | -$4.19M | -$2.41M | $5.67M | $146.97K | $54.93K | -$53.64K | -$391.56K | $519.84K | $1.06M | -$110.56K | |
| -$84.57M | -$78.09M | -$35.02M | -$31.53M | -$41.63M | — | — | — | — | — | — | — | — | — | |
| $169K | $165K | $114K | $14K | $28K | -$196K | -$2.79M | $280.32K | -$49.47K | $1.97M | $0 | $0 | — | — | |
| -$84.74M | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M | -$63.5M | -$16.07M | -$40.05M | $11.87M | -$16.47M | -$10.49M | -$16.06M | -$13.05M | |
| — | -132642.37% | -7965.76% | -1639.5% | -230.78% | -1563.1% | -947.9% | -238.1% | -569.87% | 42.68% | -1428.6% | — | — | — | |
| — | — | -$35.13M | -$31.54M | — | — | — | — | $41.7M | $7.77M | -$16.47M | -$10.49M | -$3.52M | -$13.13M | |
| -$84.75M | -$78.19M | -$35.13M | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$5.84 | -$7.94 | -$113.58 | -$1,063.00 | — | — | — | -$3,456.00 | $1,209.60 | -$5,385.60 | -$13,564.80 | — | — |
| USD/shares | — | -$5.84 | -$20.91 | -$113.58 | -$1,063.00 | — | — | — | -$3,456.00 | $1,209.60 | -$5,385.60 | -$13,564.80 | — | — |
| shares | — | 13.4M | 4.43M | 277.73K | 39.2K | — | — | — | 12.07K | 6392.3628 | 3066.1097 | 772.9247 | 222.9347 | 220.024 |
| shares | — | 13.4M | 7.5M | 277.73K | 39.2K | — | — | — | 12.07K | 6512.083 | 3066.1097 | 772.9247 | 222.9347 | 220.024 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.54×
EV/EBIT
—
Biotechnology median 25.59×
P/E (TTM)
—
Biotechnology median 7.55×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Product | $59,000 | $441,000 | $1,408,000 | $3,364,000 | $4,773,000 | $6,699,000 | $6,650,351 |
| AVTX611 | — | — | — | $200,000 | — | — | — |
| License | — | — | $516,000 | $14,687,000 | $625,000 | $0 | $100,000 |